Healthequity (HQY) Downgraded to Buy at ValuEngine

Healthequity (NASDAQ:HQY) was downgraded by ValuEngine from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.

A number of other research firms have also recently commented on HQY. Barrington Research reissued an “outperform” rating and issued a $100.00 target price on shares of Healthequity in a research note on Wednesday, September 5th. They noted that the move was a valuation call. KeyCorp increased their target price on Healthequity from $90.00 to $105.00 and gave the company an “overweight” rating in a research note on Tuesday, September 4th. BidaskClub cut Healthequity from a “buy” rating to a “hold” rating in a research note on Tuesday, November 20th. Zacks Investment Research cut Healthequity from a “buy” rating to a “hold” rating in a research note on Tuesday, November 20th. Finally, Oppenheimer increased their target price on Healthequity from $85.00 to $104.00 and gave the company an “outperform” rating in a research note on Wednesday, September 5th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $93.08.

HQY opened at $83.60 on Wednesday. The firm has a market capitalization of $5.50 billion, a P/E ratio of 154.81, a PEG ratio of 3.08 and a beta of 1.37. Healthequity has a 52 week low of $42.92 and a 52 week high of $101.58.

Healthequity (NASDAQ:HQY) last released its earnings results on Tuesday, September 4th. The company reported $0.34 EPS for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.12. The business had revenue of $71.10 million for the quarter, compared to analysts’ expectations of $69.84 million. Healthequity had a return on equity of 12.58% and a net margin of 23.81%. The firm’s revenue was up 25.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.27 earnings per share. On average, equities analysts forecast that Healthequity will post 0.87 EPS for the current year.

In other Healthequity news, VP Darcy G. Mott sold 4,000 shares of the company’s stock in a transaction dated Monday, October 22nd. The shares were sold at an average price of $87.01, for a total transaction of $348,040.00. Following the completion of the sale, the vice president now directly owns 92,500 shares in the company, valued at $8,048,425. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last 90 days, insiders have sold 12,000 shares of company stock valued at $1,027,400. Company insiders own 4.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Advisors Asset Management Inc. boosted its position in Healthequity by 5,212.2% during the second quarter. Advisors Asset Management Inc. now owns 72,086 shares of the company’s stock valued at $160,000 after buying an additional 70,729 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Healthequity during the third quarter worth about $172,000. Cerebellum GP LLC purchased a new stake in shares of Healthequity during the third quarter worth about $185,000. Sawtooth Solutions LLC purchased a new stake in shares of Healthequity during the second quarter worth about $207,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Healthequity during the third quarter worth about $210,000. Institutional investors and hedge funds own 93.01% of the company’s stock.

Healthequity Company Profile

HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Featured Story: Inflation

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit